Dr Renier Brentjens | Director, Cellular Therapeutics
Memorial Sloan-Kettering Cancer Center

Dr Renier Brentjens, Director, Cellular Therapeutics, Memorial Sloan-Kettering Cancer Center

Dr Renier J. Brentjens obtained an MD/PhD (microbiology) from SUNY Buffalo, completed residency in medicine at Yale New Haven Hospital, and a medical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC). Currently, Dr Brentjens is an associate member on the faculty at MSKCC and an attending physician on the leukemia service. Ongoing pre-clinical and clinical research in the focused on the further development of CAR modified T cells designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of “armored CAR T cells.”


WIC 2017 Day 2, Wednesday 1st November 2017 @ 12:05

Next generation CAR T cells

  • Recognize barriers to CAR T cell therapy of cancer including T cell persistence, antigen escape, and the immune suppressive tumour microenvironment
  • Recognize novel CAR T cell designs utilized to optimize anti-cancer efficacy of this novel approach as well as how these armoured CAR T cell designs may bridge the gap from liquid to solid tumours

back to speakers